Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Drugs for Genetic Disease in Preclinical Development in UNITED KINGDOM

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Evox Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO IMPACT

              Participation Not Confirmed

              Update your events

              Evox Therapeutics and Takeda Sign Multi-target Rare Disease Collaboration

              Contact the Supplier

              Lead Product(s): Protein therapeutics

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Takeda Pharmaceutical

              Deal Size: $882.0 million Upfront Cash: $44.0 million

              Deal Type: Partnership March 26, 2020

              Details:

              Deal allows Evox to continue advancing its exosome-based targeting and delivery technology, while also leveraging Takeda’s development and clinical expertise to advance these partnered programmes.

              Enterprise Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO IMPACT

              Participation Not Confirmed

              Update your events

              Enterprise Therapeutics Publishes Paper on Novel Therapeutic Approach for Treatment of All Cystic Fibrosis Patients

              Contact the Supplier

              Lead Product(s): ETX001

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 08, 2020

              Details:

              Paper demonstrates first in class TMEM16A chloride channel potentiators, to accelerate mucociliary clearance.

              PharmaCompass__DigitalAd